Core Viewpoint - Ocumetics Technology Corp. has appointed Raymond Marks to its Board of Directors, leveraging his extensive experience in capital markets and fundraising to support the company's next stage of growth [1][4]. Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions aimed at enhancing patients' quality of life [5]. - The company is currently in the early feasibility study phase for a revolutionary intraocular lens technology designed to eliminate the need for corrective lenses, allowing natural focus adjustment for clear vision at all distances [6]. Leadership Experience - Raymond Marks has over 50 years of experience as an entrepreneur and manager across various industries, including resources and industrial sectors, and has successfully secured millions in financing for strategic initiatives [2]. - He co-founded Tudor Gold Corp. and served as executive Vice President and director, later assisting in the formation of Hanstone Capital Corporation, where he was President and CEO, helping to secure over $16 million in financing for both companies [3].

Core Viewpoint - Ocumetics Technology Corp. has entered into a forbearance agreement with debentureholders, allowing them to defer payment on secured convertible debentures until June 19, 2027, despite the original maturity date [1]. Group 1: Forbearance Agreement - The forbearance agreement involves debentures with a total face value of up to $4,000,000, bearing an interest rate of 18% per annum, compounded annually [2]. - The Corporation can prepay the debentures with a 90-day prior written notice without incurring penalties [2]. - The principal amount of the debentures is convertible into common shares at a price of $0.32 per share until the maturity date [3]. Group 2: Warrants Issuance - In exchange for the forbearance, Ocumetics issued 9,153,277 share purchase warrants to debentureholders, allowing them to purchase common shares at an exercise price of $0.58 until June 19, 2027 [4]. - The warrants are classified as bonus warrants under TSX Venture Exchange Policy 5.1, with specific terms regarding repayment or conversion of the debentures [4]. Group 3: Offering Details - The previously announced offering under the listed issuer financing has terminated, with 1,706,383 units sold at a price of $0.60 per unit, generating approximately $1,023,830 in gross proceeds [5]. - Each unit consists of one common share and one common share purchase warrant, with the warrant allowing purchase of an additional common share at $0.75 until December 30, 2028 [5]. Group 4: Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions aimed at enhancing patients' quality of life [6]. - The company is in the early feasibility study phase of developing a revolutionary intraocular lens designed to eliminate the need for corrective lenses, allowing natural focus adjustment [8].

Core Viewpoint - Ocumetics Technology Corp. is seeking approval for a forbearance agreement with holders of secured convertible debentures, allowing them to defer payment until June 19, 2027 [1][2]. Group 1: Forbearance Agreement - The proposed forbearance agreement involves Debentureholders refraining from demanding payment or taking action on security until June 19, 2027, despite the maturity of the Debentures [1]. - The Debentures have a total face value of up to $4,000,000, with an interest rate of 18% per annum, compounded annually [2]. - The Corporation can prepay the Debentures at any time with a 90-day prior written notice, without incurring penalties [2]. Group 2: Debenture Terms - The Principal amount of the Debentures is convertible into common shares at a price of $0.32 per share until the Maturity Date [3]. - Interest on the Debentures can also be converted into common shares, subject to Exchange approval [3]. - The Debentures are secured by a general security agreement on the Corporation's personal property [3]. Group 3: Warrants Issuance - In exchange for the forbearance, the Corporation plans to issue share purchase warrants to Debentureholders, calculated based on the Principal and accrued interest divided by $0.58 [4]. - Each Warrant will allow the holder to purchase one common share at an exercise price of $0.58 until the earlier of June 19, 2027, or when the indebtedness is fully repaid [4]. Group 4: Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions [5]. - The company is in the early feasibility study phase of a new intraocular lens technology designed to eliminate the need for corrective lenses, allowing natural focus adjustment [6].

Core Viewpoint - Ocumetics Technology Corp. has amended the terms of its previously announced brokered private placement, aiming to raise up to $2.5 million through the issuance of units at an amended price of $0.60 per unit [1][2]. Group 1: Offering Details - The amended offering will consist of up to 4,166,666 units, each unit comprising one common share and one common share purchase warrant, with the warrant allowing the purchase of a share at $0.75 for three years [2]. - The Lead Agent has been granted an option to sell an additional 625,000 units at the same price, potentially raising an extra $375,000 [3]. - The offering is expected to close around December 29, 2025, subject to necessary approvals [7]. Group 2: Use of Proceeds - The gross proceeds from the offering are intended to fund the Corporation's first-in-human clinical trials, ongoing research and development, and general corporate purposes [4]. Group 3: Regulatory and Compliance - The units will be offered through a private placement under specific exemptions in Canada and the United States, with no prospectus filing required in certain jurisdictions [5]. - Participation by insiders in the offering will be considered a related party transaction but is expected to be exempt from formal valuation and minority shareholder approval requirements [8]. Group 4: Company Overview - Ocumetics Technology Corp. is focused on developing advanced vision correction solutions, including innovative intraocular lenses designed to eliminate the need for corrective lenses [10][11].

Core Insights - Ocumetics Technology Corp. is participating in the 2025 Maxim Growth Summit, highlighting its role as a leader in advanced ophthalmic technology [1][2] - The company is currently in the early feasibility study phase for a revolutionary intraocular lens designed to provide clear vision at all distances without corrective lenses [5] Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions aimed at enhancing patients' quality of life [4] - The company is dedicated to transforming ophthalmology through innovative research and development of state-of-the-art intraocular lenses and other vision-enhancing technologies [4] Event Participation - Dean Burns, President and CEO of Ocumetics, will participate in a panel titled 'A vision of Innovation' at the Maxim Growth Summit [2] - The summit will feature keynote speakers and roundtable discussions covering various topics, including biotechnology and ophthalmology [3] Technology Development - Ocumetics is developing an intraocular lens that fits within the natural lens compartment of the eye, potentially eliminating the need for glasses or contact lenses [5] - The lens is designed to utilize the eye's natural muscle activity to shift focus, providing clear vision at all distances [5]

Group 1 - Ocumetics Technology Corp. has engaged Howard Group Inc. as its investor relations communications advisor for a six-month period starting September 1, 2025, with a monthly compensation of $10,000 and additional fees as needed [1][2] - The agreement includes granting Howard Group stock options to purchase up to 250,000 common shares for two years at market price, with an additional 250,000 options if the contract is extended [1] - The engagement is subject to the approval of the TSX Venture Exchange, which is currently pending [2] Group 2 - Ocumetics is a Canadian research and product development company focused on advanced vision correction solutions aimed at enhancing patients' quality of life [3] - The company is in the preclinical study phase of developing a revolutionary intraocular lens designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses [4] - This intraocular lens is intended to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses [4]

Core Viewpoint - Ocumetics Technology Corp. has successfully completed the first tranche of a private placement, raising a total of $1,124,362 through the issuance of 3,212,462 units at a price of $0.35 per unit [1][2]. Group 1: Private Placement Details - The units issued consist of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of an additional common share at an exercise price of $0.50 for 24 months [2]. - The total offering aims to raise up to $2,100,000 by issuing up to 6,000,000 units at the same price, with the remaining tranches to be closed subsequently [5]. - The net proceeds from the offering are intended for ongoing research and development, although actual allocation may vary based on future operations [5]. Group 2: Agent and Related Transactions - Ocumetics paid $68,610 to Numus Capital Corp. for their services as an agent and issued warrants allowing Numus Capital to purchase up to 196,029 common shares at $0.50 per share for 24 months [3]. - The private placement involved a related party transaction, as a director of the Corporation participated, and the transaction was approved unanimously by the board [6]. Group 3: Company Overview - Ocumetics Technology Corp. is focused on developing advanced vision correction solutions, including innovative intraocular lenses aimed at enhancing the quality of life for patients [7][8]. - The company is currently in the preclinical study stage of a technology designed to potentially eliminate the need for corrective lenses by allowing the eye's natural muscle activity to shift focus [9].